Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Risks and capability

Four synthetic biology risk objects open the portfolio. Order carries no rank. Each is read across driver, exposure, vulnerability, capacity, cascade and consequence.

7 min read0 figures1 table23 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

విషయసూచిక
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
    1. 4.1 Risk objects
    2. 4.2 Capability ladder
  7. 5Design capability outpaces screening and oversight
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

4.1Risk objects

Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.

  1. InferredEQL 3RSK-XT04-SEC-001

    Design capability outpaces screening

    Driver
    open machine-learning design tools and low-cost DNA713
    బహిర్గతం
    sequence-handling and synthesis providers
    దుర్బలత్వం
    uneven screening practice; benchtop and small providers
    సామర్థ్యం
    screening guidance, patches and oversight frameworks13253132
    పరంపర
    DAT → BIO → HLT
    Horizon
    1 to 5 years
  2. InferredEQL 3RSK-XT04-GOV-002

    Fragmented and shifting oversight

    Driver
    US framework not updated after the 2025 order; separate EU and CBD tracks20222627
    బహిర్గతం
    research collaboration; cross-border orders
    దుర్బలత్వం
    uneven implementation across jurisdictions18
    సామర్థ్యం
    OECD and WHO guidance; national strategies1821
    పరంపర
    GOV → BIO, FIN
    Horizon
    1 to 5 years
  3. Expert inputEQL 2RSK-XT04-SUP-003

    Manufacturing base thinner than headlines

    Driver
    mixed company results and planning-stage public awards161724
    బహిర్గతం
    products that depend on scale-up
    దుర్బలత్వం
    few counted facilities; unmeasured feedstock needs
    సామర్థ్యం
    institute and awards programme2324
    పరంపర
    FIN → INF → BIO
    Horizon
    1 to 10 years
  4. InferredEQL 2RSK-XT04-ENV-004

    Release and novel-organism questions

    Driver
    gene drives and organisms with altered codes or chirality11112
    బహిర్గతం
    ecosystems; public trust
    దుర్బలత్వం
    limited field evidence; international rules still forming
    సామర్థ్యం
    CBD process and protocol2035
    పరంపర
    BIO → BIO biodiversity systems
    Horizon
    5 to 10 years

4.2Capability ladder

Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for synthetic biology at the global level.

Table 4.1Capabilities on the ladder of evidence: listed, exists, demonstrated, tested
FunctionRungస్థాయిStrongest public evidence at baseline
Prevention and mitigationEXISTSscreening guidance and dual-use frameworks published212531
Monitoring and observationLISTEDno common tracker of synthesis orders or screening coverage
Early warningLISTEDhorizon scanning exists under the CBD but is scaled back20
Preparedness and planningEXISTSUS commission report, EU proposal and OECD papers141822
Redundancy and reservesLISTEDmanufacturing capacity and reserves not counted
ప్రతిస్పందనLISTEDno tested response to a misuse event described in the sources
Continuity of critical servicesLISTEDnot reviewed
RecoveryLISTEDnot applicable at baseline; no event to recover from
AdaptationEXISTSanticipatory governance principles in OECD work1819
Social protectionLISTEDnot applicable at baseline
Finance and insuranceLISTEDpublic and private investment not on a common basis
Institutional coordinationEXISTSWHO, CBD and OECD processes182021
Technical infrastructureEXISTSbioindustrial institute and planning awards2324
WorkforceLISTEDskills gaps reported in policy documents; no figure bound
Research capacityADEQUATEstrong peer-reviewed base1467
A capability listed in policy is not a tested one; each rung is the strongest public evidence at baseline.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  3. 25National Science and Technology Council, Fast Track Action Committee on Synthetic Nucleic Acid Procurement Screening (ed.), Framework for Nucleic Acid Synthesis Screening (version 1 April 2024, revised September 2024; framework document read). Office of Science and Technology Policy, Washington. Observation year 2024. Accessed 2026-11-05.back
  4. 31International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol v3.1, 1 June 2026 (document read; common sequence and customer screening practice of IGSC members). IGSC. Observation year 2026. Accessed 2026-11-05.back
  5. 32Department for Science, Innovation and Technology (ed.), UK screening guidance on synthetic nucleic acids for users and providers, 8 October 2024 (guidance page read). DSIT, London. Observation year 2024. Accessed 2026-11-05.back
  6. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
  7. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
  8. 26The White House (ed.), Executive Order 14292 of 5 May 2025, Improving the Safety and Security of Biological Research, Federal Register 2025-08266, 8 May 2025 (text read; section 4(b) gives OSTP 90 days to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening). Office of the Federal Register, Washington. Observation year 2025. Accessed 2026-11-05.back
  9. 27Congressional Research Service (ed.), Artificial Intelligence and Biosecurity Issues, CRS In Focus IF13269, 16 July 2026, updated 3 August and 15 September 2026 (all three versions read; the July version states that CRS could not determine whether the 2024 policy and the 2024 screening framework had been revised or replaced; the September update states that a July 2026 policy replaced the 2024 dual-use research policy and that OSTP had not updated the 2024 screening framework). Library of Congress, Washington. Observation year 2026. Accessed 2026-11-05.back
  10. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
  11. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
  12. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
  13. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
  14. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
  15. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
  16. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  17. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
  18. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
  19. 35Secretariat of the Convention on Biological Diversity (ed.), The Cartagena Protocol on Biosafety to the Convention on Biological Diversity (protocol page read; adopted 29 January 2000; in force since 11 September 2003; governs living modified organisms). CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-05.back
  20. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
  21. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
  22. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
  23. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • Print

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF116 pages1.1 MBTagged, with bookmarks

      SHA-256 639c56cefb1949003c7c12afb373872ca06a7a9d2636ed3a03036421f5a0667e

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF124 pages1.1 MBTagged, with bookmarks

      SHA-256 809ea48a7122779a508bafef6382f20f37c4aec32bc811e35c132e78757714e8

  • Web edition

  • Data bundle

    • Indicators, CSV

      21 indicators with unit, year, status and source

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.csv2 KB

      SHA-256 ad80b1f5ddbd91cc3df1a06ae20fc038c8db1504b94d5d927e92cf4654cd1ef9

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.json3 KB

      SHA-256 42ed0ca7518f347165dbd95fe4869ad99cc319a622d910a46b91989f1f5b7e08

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-findings.csv4 KB

      SHA-256 1adaa8152308fb73ac5dd085a986cd24ce190e4728716aa4ff4a1b50a4e68f87

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 ea099771745b82b9d4f32643f1660d265a4d736b13c87edd7f1d406f3f019d07

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 17ed68ee662c0db11b3426eaeb65535f5fd14473a85160734886ccf70a44423b

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 0b1b02fec9505a958f1baaab6932ca483182ef925f5b68fadb22734159e1daea

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 4: Risks and capability. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

నివేదికలుసహకరించండి

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology
Contribution form · reports.contribution.gcri

వ్యక్తిగత డేటా, సున్నితమైన మౌలిక సదుపాయాల వివరాలు లేదా పంచుకునే హక్కు మీకు లేని దేనినీ ఎప్పుడూ పంపవద్దు. సహకారం ఉపయోగానికి ముందు సమీక్షించబడుతుంది; దానిని పంపడం వల్ల రచయిత్వం లేదా సంపాదకీయ హక్కులు లభించవు, మరియు స్పాన్సర్‌షిప్ ఎప్పుడూ ఒక నిర్ధారణను కొనలేదు.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

Your role here

What you can do from this page.

  • ReaderFound an error? Every correction is public.Corrections log
  • ContributorSend evidence, data or a correction to this desk.Contribute
  • ReviewerReview for this desk; verified reviews are credited.Become a reviewer
  • Editor, steward or boardQueues, decisions and production are in the workspace.My workspace